A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
出版年份 2020 全文链接
标题
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-10-05
DOI
10.1038/s41416-020-01099-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
- (2019) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: implications for combination therapies
- (2019) Yijun Jia et al. INTERNATIONAL JOURNAL OF CANCER
- Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
- (2018) Xue Li et al. CANCER LETTERS
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
- (2018) Paul G. Baverel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- Nivolumab Plus Erlotinib in Patients With EGFR -Mutant Advanced NSCLC
- (2018) Scott Gettinger et al. Journal of Thoracic Oncology
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor
- (2018) K Kunimasa et al. ANNALS OF ONCOLOGY
- Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation
- (2018) Shan Su et al. Journal of Thoracic Oncology
- A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing
- (2018) Patrick H. Lizotte et al. Cancer Immunology Research
- Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
- (2018) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
- (2018) Michael Offin et al. CLINICAL CANCER RESEARCH
- Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
- (2017) Kenneth S. Thress et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
- (2016) Marlon C. Rebelatto et al. Diagnostic Pathology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin
- (2016) Daniela Lulli et al. Oncotarget
- Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
- (2015) M. Schuler et al. ANNALS OF ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
- (2015) Yanna Tang et al. Oncotarget
- Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
- (2015) R. Stewart et al. Cancer Immunology Research
- PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
- (2015) Lars Henning Schmidt et al. PLoS One
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
- (2014) Yi Ling Teo et al. Expert Opinion on Drug Metabolism & Toxicology
- Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
- (2014) Stéphane Champiat et al. Journal of Thoracic Oncology
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
- (2013) T Kumai et al. BRITISH JOURNAL OF CANCER
- Advanced health biotechnologies in Thailand: redefining policy directions
- (2013) Román Pérez Velasco et al. Journal of Translational Medicine
- Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
- (2011) B. P. Pollack et al. CLINICAL CANCER RESEARCH
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started